Analysis

Prior Defects Could Sink Auvi-Q Even As EpiPen Prices Soar

By Dani Kass (October 31, 2016, 4:52 PM EDT) -- Lawmakers and consumers calling for a competitor to challenge Mylan NV in the aftermath of the drugmaker's EpiPen price increases may not have gotten what they wanted with Kaléo Pharma's Auvi-Q, as experts say defects that drove Auvi-Q off the market nearly two years ago may overshadow any price cuts.

Kaléo has a "golden opportunity" to carve out a place in the epinephrine injector market when it launches Auvi-Q in 2017 given the legal, regulatory and public scrutiny Mylan is still undergoing, but the product's history will make doing so difficult, says Eric Fader of Day Pitney LLP. Auvi-Q's past owner, Sanofi-Aventis SA,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!